{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:04:42Z","timestamp":1794233082429,"version":"4.9.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 54-year-old man with multiple endocrine neoplasia type 1 had previous history of parathyroid surgery and left thyroid lobectomy 5 years earlier, and was referred for recurrent hypoglycemic episodes. <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT had showed multiple lesions in the right lung, liver, and pancreas. Biopsy from pancreas revealed low-grade neuroendocrine neoplasia. After 2 fractions of <jats:sup>177<\/jats:sup>Lu-DOTATATE therapy, the size of lesions and its activity reduced on the <jats:sup>68<\/jats:sup>Ga-DOTATATE scan and the hypoglycemic episodes manifested every day have scaled down to 1 time over 1-year follow-up. Herein, we report a case of malignant insulinoma successfully treated with radiolabeled somatostatin receptor therapy using <jats:sup>177<\/jats:sup>Lu-DOTATATE.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002500","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T12:46:35Z","timestamp":1550753195000},"page":"e415-e417","source":"Crossref","is-referenced-by-count":9,"title":["Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome"],"prefix":"10.1097","volume":"44","author":[{"given":"Fuad","family":"Novruzov","sequence":"first","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mehmetbeyli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil A.","family":"Aliyev","sequence":"additional","affiliation":[{"name":"General Surgery, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahadur","family":"Abbasov","sequence":"additional","affiliation":[{"name":"Pathology, National Centre of Oncology, Baku, Azerbaijan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnur","family":"Mehdi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1530\/EJE-13-1012","article-title":"Management of endocrine disease: a clinical update on tumor-induced hypoglycemia","volume":"170","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"bib2-20230925","first-page":"273","article-title":"Combined octreotide and peptide receptor radionuclide therapy ((90) Y-DOTA-TATE) in case of malignant insulinoma","volume":"33","year":"2012","journal-title":"Neuro Endocrinol Lett"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00268-005-7743-y","article-title":"Malignant metastatic insulinoma\u2014postoperative treatment and follow-up","volume":"29","year":"2005","journal-title":"World J Surg"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnmt.115.168146","article-title":"177Lu-DOTATATE PRRT in patients with metastatic neuroendocrine tumor and a single functioning kidney: tolerability and effect on renal function","volume":"44","year":"2016","journal-title":"J Nucl Med Technol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201906000-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:11:29Z","timestamp":1695618689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201906000-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002500","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}